替罗非班在急性缺血性卒中再灌注治疗中的应用

Application of tirofiban in reperfusion treatment of acute ischemic stroke

替罗非班是一种非肽选择性糖蛋白Ⅱb/Ⅲa受体抑制剂,能可逆性抑制纤维蛋白原依赖性血小板聚集和随后的血栓形成。血小板活化导致的血栓形成在缺血性脑血管事件的发生和发展中起着至关重要的作用。一些研究对替罗非班在静脉溶栓和血管内治疗中的应用进行过评价。尽管最佳剂量、使用条件和目标患者尚未完全明确,但替罗非班的良好耐受性以及在改善血管再通和长期功能转归方面的疗效已得到验证。文章对替罗非班的作用机制及其在急性缺血性卒中再灌注治疗中的应用进行了综述。

Tirofiban is a selective non-peptide glycoproteinⅡb/Ⅲa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent thrombosis.Thrombosis caused by platelet activation plays a vital role in the occurrence and development of ischemic cerebrovascular events.Some studies have evaluated the use of tirofiban in intravenous thrombolysis and endovascular therapy.Although the optimal dose,conditions of use,and target patients have not been fully identified,the good tolerability of tirofiban and its efficacy in improving recanalization and long-term functional outcomes have been validated.This article reviews the mechanism of tirofiban and its application in the treatment of acute ischemic stroke reperfusion.